Short-term Predictive Value of SST2 in Patients with STEMI Following Primary PCI: a Prospective Observational Study

Overview

Journal BMC Cardiovasc Disord

Publisher Biomed Central

Date 2025 Jan 17

PMID 39819309

Authors

Shan Huang

Lu-Jiao Yu

Guang-Feng Sun

Zi-Xin Zhang

Affiliations

Soon will be listed here.

Abstract

Aim: The objective of this study was to investigate the level of soluble suppression of tumorigenicity-2 (sST2) in patients with acute ST-segment elevation myocardial infarction (STEMI) following primary percutaneous coronary intervention (PCI), and to provide a new biomarker for clinical management and prognosis assessment.

Method: This was a prospective study. 148 STEMI patients following primary PCI were enrolled and divided into 2 groups by the median value of sST2 and afterwards followed up for 30 days to access the occurrence of major adverse cardiac events (MACEs), which were defined as cardiovascular death, heart failure and recurrent MI.

Results: sST2 ranged from 20.57 to 98.96 ng/mL. High sST2 group had higher MACEs rate compared to low sST2 group (28.8% vs. 8.0%, P = 0.001). sST2 was positively correlated with age (r = 0.181, P = 0.027), SYNTAX score (r = 0.257, P = 0.002), high-sensitive C-reactive protein (hs-CRP) (r = 0.225, P = 0.006), B-type natriuretic peptide (BNP) (r = 0.225, P = 0.006) and negatively with left ventricle ejection fraction (LVEF) (r = -0.197, P = 0.016). After adjustment for clinical variables, sST2 level (OR 3.680, P = 0.015) and LVEF (OR 0.880, P < 0.001) remained independent predictors of 30-days MACEs. In receiver operating characteristic curve (ROC) analyses, the area under the curve (AUC) of sST2 for predicting 30-days MACEs was 0.755(P < 0.001). The AUC of sST2 combining hs-CRP and LVEF for prediction was 0.828(95%CI [0.743-0.912], P < 0.001).

Conclusion: sST2 level after primary PCI was an independent risk factor of MACEs in STEMI patients through 30 days follow-up.

References

Chen W, Lin A, Yu Y, Zhang L, Yang G, Hu H . Serum Soluble ST2 as a Novel Inflammatory Marker in Acute Ischemic Stroke. Clin Lab. 2018; 64(9):1349-1356. DOI: 10.7754/Clin.Lab.2018.180105. View

Gruzdeva O, Dyleva Y, Uchasova E, Akbasheva O, Karetnikova V, Kashtalap V . Biological markers and cardiac remodelling following the myocardial infarction. Aging (Albany NY). 2019; 11(11):3523-3535. PMC: 6594818. DOI: 10.18632/aging.101994. View

Willems S, Sels J, Flier S, Versteeg D, Buhre W, de Kleijn D . Temporal changes of soluble ST2 after cardiovascular interventions. Eur J Clin Invest. 2012; 43(2):113-20. DOI: 10.1111/eci.12022. View

Zhang Q, Hu M, Ma S . Association of Soluble Suppression of Tumorigenicity with No-Reflow Phenomenon and Long-Term Prognosis in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome after Percutaneous Coronary Intervention. J Atheroscler Thromb. 2021; 28(12):1289-1297. PMC: 8629709. DOI: 10.5551/jat.59832. View

Sanada S, Hakuno D, Higgins L, Schreiter E, McKenzie A, Lee R . IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007; 117(6):1538-49. PMC: 1865027. DOI: 10.1172/JCI30634. View

Wang Y, Wang J, Wang X, Liu J, Jiang F, Huang X . Roles of ST2, IL-33 and BNP in predicting major adverse cardiovascular events in acute myocardial infarction after percutaneous coronary intervention. J Cell Mol Med. 2017; 21(11):2677-2684. PMC: 5661109. DOI: 10.1111/jcmm.13183. View

Wang T, Wollert K, Larson M, Coglianese E, McCabe E, Cheng S . Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation. 2012; 126(13):1596-604. PMC: 3656719. DOI: 10.1161/CIRCULATIONAHA.112.129437. View

Lin Y, Zhang R, Hou L, Wang K, Ye Z, Huang T . Distribution and clinical association of plasma soluble ST2 during the development of type 2 diabetes. Diabetes Res Clin Pract. 2016; 118:140-5. DOI: 10.1016/j.diabres.2016.06.006. View

Thomas M, Bates E . Update on primary PCI for patients with STEMI. Trends Cardiovasc Med. 2016; 27(2):95-102. DOI: 10.1016/j.tcm.2016.06.010. View

10.

Biccire F, Farcomeni A, Gaudio C, Pignatelli P, Tanzilli G, Pastori D . D-dimer for risk stratification and antithrombotic treatment management in acute coronary syndrome patients: asystematic review and metanalysis. Thromb J. 2021; 19(1):102. PMC: 8684263. DOI: 10.1186/s12959-021-00354-y. View

11.

Liu X, Hu Y, Huang W, Zhang G, Cao S, Yan X . Soluble ST2 for Prediction of Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Receiving Primary PCI. Int Heart J. 2018; 60(1):19-26. DOI: 10.1536/ihj.18-020. View

12.

Kohli P, Bonaca M, Kakkar R, Kudinova A, Scirica B, Sabatine M . Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem. 2011; 58(1):257-66. PMC: 4277435. DOI: 10.1373/clinchem.2011.173369. View

13.

Pascual-Figal D, Januzzi J . The biology of ST2: the International ST2 Consensus Panel. Am J Cardiol. 2015; 115(7 Suppl):3B-7B. DOI: 10.1016/j.amjcard.2015.01.034. View

14.

Zagidullin N, Motloch L, Gareeva D, Hamitova A, Lakman I, Krioni I . Combining Novel Biomarkers for Risk Stratification of Two-Year Cardiovascular Mortality in Patients with ST-Elevation Myocardial Infarction. J Clin Med. 2020; 9(2). PMC: 7073894. DOI: 10.3390/jcm9020550. View

15.

Mueller T, Zimmermann M, Dieplinger B, Jan Ankersmit H, Haltmayer M . Comparison of plasma concentrations of soluble ST2 measured by three different commercially available assays: the MBL ST2 assay, the Presage ST2 assay, and the R&D ST2 assay. Clin Chim Acta. 2012; 413(19-20):1493-4. DOI: 10.1016/j.cca.2012.06.021. View

16.

Minana G, Nunez J, Bayes-Genis A, Revuelta-Lopez E, Rios-Navarro C, Nunez E . ST2 and left ventricular remodeling after ST-segment elevation myocardial infarction: A cardiac magnetic resonance study. Int J Cardiol. 2018; 270:336-342. DOI: 10.1016/j.ijcard.2018.06.073. View

17.

Sabatine M, Morrow D, Higgins L, Macgillivray C, Guo W, Bode C . Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008; 117(15):1936-44. PMC: 4273564. DOI: 10.1161/CIRCULATIONAHA.107.728022. View

18.

Jha D, Goenka L, Ramamoorthy T, Sharma M, Dhandapani V, George M . Prognostic role of soluble ST2 in acute coronary syndrome with diabetes. Eur J Clin Invest. 2018; 48(9):e12994. DOI: 10.1111/eci.12994. View

19.

Zeng Y, Xue M, Zhang T, Sun S, Lin R, Li N . Soluble form of suppression of tumorigenicity-2 predicts clinical stability of inpatients with community-acquired pneumonia. Exp Biol Med (Maywood). 2021; 246(21):2297-2306. PMC: 8581825. DOI: 10.1177/15353702211027116. View

20.

Somuncu M, Akgun T, Cakir M, Akgul F, Serbest N, Karakurt H . The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. J Atheroscler Thromb. 2019; 26(11):970-978. PMC: 6845696. DOI: 10.5551/jat.48413. View